0 CHECKOUT
Colorectal Cancer Therapeutics Market in APAC 2015-2019 - Product Image

Colorectal Cancer Therapeutics Market in APAC 2015-2019

  • ID: 3517377
  • December 2015
  • 106 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Accord Healthcare
  • Bayer Healthcare
  • Daiichi Sankyo
  • Immodulon Therapeutics
  • Morphotek
  • PsiOxus Therapeutics
  • MORE

About colorectal cancer
Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.

The report forecasts the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.

Covered in this report
The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales READ MORE >

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Accord Healthcare
  • Bayer Healthcare
  • Daiichi Sankyo
  • Immodulon Therapeutics
  • Morphotek
  • PsiOxus Therapeutics
  • MORE

PART 01: Executive summary
- Highlights

PART 02: Scope of the report
- Market overview
- Top-vendor offerings
- Vectibix

PART 03: Product profiles
- Stivarga
- Erbitux
- Xeloda
- Avastin
- Zaltrap

PART 04: Market research methodology
- Research methodology
- Economic indicators

PART 05: Introduction
- Key market highlights

PART 06: Disease overview
- Understanding the disease
- High risk factors
- Signs and symptoms
- Pathophysiology
- Diagnosis
- Staging
- Biomarker testing
- Epidemiology
- Treatment

PART 07: Pipeline portfolio
- Information on pipeline candidates

PART 08: Market landscape
- Market overview
- Market size and forecast
- Colorectal cancer therapeutics market in Japan
- Colorectal cancer therapeutics market in China
- Five forces analysis

PART 09: Market segmentation by based on the type of molecules
- Small molecules
- Biologics

PART 10: Market segmentation by route of administration
- Oral
- Parenteral

PART 11: Market segmentation by lines of chemotherapy
- First-line chemotherapy
- Second-line chemotherapy

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape
- Competitive scenario
- Market share analysis 2014
- Other prominent vendors
- Amgen

PART 18: Key vendor analysis
- Bayer HealthCare
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Merck
- Sanofi

PART 19: Appendix
- List of abbreviations

PART 20: About the Author

Exhibit 01: Product offerings
Exhibit 02: High risk factors for colorectal cancer
Exhibit 03: Signs and symptoms of colorectal cancer
Exhibit 04: Diagnostic tests for colorectal cancer
Exhibit 05: Staging for colon cancer
Exhibit 06: Staging for rectal cancer
Exhibit 07: Types of genes
Exhibit 08: Estimated incidence, mortality, and five-year prevalence per 100,000 in APAC 2012
Exhibit 09: Colorectal cancer mortality rates in APAC 2012 (rate per 100,000 population)
Exhibit 10: Incidence rates of colorectal cancer in Asia, 2011 (rate per 100,000 population)
Exhibit 11: Estimated incidence in adult population in APAC 2012
Exhibit 12: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, males
Exhibit 13: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, females
Exhibit 14: Treatment options for colorectal cancer
Exhibit 15: Types of surgical procedure for colorectal cancer
Exhibit 16: Types of radiation therapy for colorectal cancer
Exhibit 17: Types of targeted therapy
Exhibit 18: Summary of approved cancer drugs for colon cancer
Exhibit 19: Pipeline molecules for colorectal cancer
Exhibit 20: Colorectal cancer therapeutics market in APAC ($ billions)
Exhibit 21: Colorectal cancer therapeutics market in Japan 2014-2019 ($ billions)
Exhibit 22: Colorectal cancer therapeutics market in China 2014-2019 ($ millions)
Exhibit 23: Five forces analysis
Exhibit 24: Colorectal cancer therapeutics market in APAC segmented by molecule type
Exhibit 25: Colorectal cancer therapeutics market in APAC segmented by route of administration
Exhibit 26: Summary of chemotherapy drugs for the treatment of colorectal cancer
Exhibit 27: Use of branded targeted therapies in China and Japan 2013
Exhibit 28: Drivers of colorectal cancer therapeutics market in APAC
Exhibit 29: Impact of drivers
Exhibit 30: Challenges of colorectal cancer therapeutics market in APAC
Exhibit 31: Impact of drivers and challenges
Exhibit 32: Trends of colorectal cancer therapeutics market in APAC
Exhibit 33: Vectibix: YoY revenue and growth rate in Japan 2011-2013 ($ millions)
Exhibit 34: Amgen: Key takeaways
Exhibit 35: Bayer: Key takeaways
Exhibit 36: Bristol-Myers Squibb: Key takeaways
Exhibit 37: Avastin: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
Exhibit 38: Xeloda: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
Exhibit 39: Chugai Pharmaceutical: Key takeaways
Exhibit 40: Merck: Key takeaways
Exhibit 41: Sanofi: Key takeaways
Exhibit 42: Amgen: Business segmentation by revenue 2014
Exhibit 43: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: Amgen: Geographical segmentation by revenue 2014
Exhibit 45: Bayer HealthCare: Business segmentation by revenue 2014
Exhibit 46: Bayer HealthCare: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 47: Bayer HealthCare: Geographical segmentation by revenue 2014
Exhibit 48: Bristol-Myers Squibb: Products segmentation by revenue FY2014
Exhibit 49: Bristol-Myers Squibb: Revenue comparison by product segmentation by FY2013 and FY2014
Exhibit 50: Bristol-Myers Squibb: Geographical segmentation by FY2014 ($ millions)
Exhibit 51: Bristol-Myers Squibb: Revenue comparison by geographical segment by FY2013 and FY2014 ($ millions)
Exhibit 52: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
Exhibit 53: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 54: Merck: Business segmentation by revenue 2014
Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 56: Merck: Geographical segmentation by revenue 2014
Exhibit 57: Sanofi: Business segmentation by revenue 2014
Exhibit 58: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 59: Sanofi: Geographical segmentation by revenue 2014

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Accord Healthcare
  • Bayer Healthcare
  • Daiichi Sankyo
  • Immodulon Therapeutics
  • Morphotek
  • PsiOxus Therapeutics
  • MORE

New Report Released: – Colorectal Cancer Therapeutics Market in APAC 2015-2019

The author of the report recognizes the following companies as the key players in the Colorectal Cancer Therapeutics Market in APAC: Amgen, Bayer Healthcare, Bristol-Myers Squibb, Chugai Pharmaceutical, Merck and Sanofi

Other Prominent Vendors in the market are: Accord Healthcare, Advenchen Laboratories, Aeterna Zentaris, AstraZeneca, AVEO Oncology, Bavarian Nordic, Biothera, Boehringer Ingelheim, Boston Biomedical, Celator Pharmaceuticals, Cancer Prevention Pharmaceuticals, Daiichi Sankyo, Debiopharm, Eisai, Eli Lilly, EpicentRx, GlaxoSmithKline, Hutchison Medipharma, Immodulon Therapeutics, Immunomedics, MacroGenics, Merrimack Pharmaceuticals, Morphotek, Mologen, MolMed, Mylan, Nektar Therapeutics, Oncothyreon, Otsuka Pharmaceutical, Precision Biologics, PsiOxus Therapeutics, PledPharma, Sun Pharmaceutical, Symphogen, Taiho, Takeda, Teva, ThromboGenics, Xbiotech, and Yakult Honsha.

Commenting on the report, an analyst from the research team said: “Biologics are one of the treatment choices for colorectal cancer. These are targeted therapies, which act only on the malignant cells and do not destroy the healthy cells. Biologics that are used for treating colorectal cancer include Avastin (bevacizumab), Erbitux (cetuximab), Vectibix (panitumumab) and Zaltrap (ziv-Aflibercept). These drugs together accounted for the major share of the market, and the same trend is expected to continue during the forecast period.”

According to the report, many drug makers assist patients financially and enable access to medicines. Patient access programs are designed to fit the needs of individuals with colorectal cancer. For instance, Sanofi’s "Sanofi Patient Connection" program aims to increase access to Zaltrap by providing free prescription medications and financial assistance. Bayer has introduced "Stivarga Reach Program" to provide co-pay assistance to patients. F. Hoffmann-La Roche's "Genentech Access Solutions" is another such program that covers the treatment expenses of patients using Avastin, or provides reimbursement support or co-pay assistance, if the patients fulfill certain criteria.

Further, the report states that the high cost of treatment of colorectal cancer is a major challenge the colorectal cancer therapeutics market in APAC is expected to experience during the forecast period.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Note: Product cover images may vary from those shown
4 of 5

- Amgen
- Bayer Healthcare
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Merck
- Sanofi
- Accord Healthcare
- Advenchen Laboratories
- Aeterna Zentaris
- AstraZeneca
- AVEO Oncology
- Bavarian Nordic
- Biothera
- Boehringer Ingelheim
- Boston Biomedical
- Celator Pharmaceuticals
- Cancer Prevention Pharmaceuticals
- Daiichi Sankyo
- Debiopharm
- Eisai
- Eli Lilly
- EpicentRx
- GlaxoSmithKline
- Hutchison Medipharma
- Immodulon Therapeutics
- Immunomedics
- MacroGenics
- Merrimack Pharmaceuticals
- Morphotek
- Mologen
- MolMed
- Mylan
- Nektar Therapeutics
- Oncothyreon
- Otsuka Pharmaceutical
- Precision Biologics
- PsiOxus Therapeutics
- PledPharma
- Sun Pharmaceutical
- Symphogen
- Taiho
- Takeda
- Teva
- ThromboGenics
- Xbiotech
- Yakult Honsha.

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Celgene Corporation
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Merck & Co., Inc.
  • Bristol-Myers Squibb